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The effects of llecainide on defibrillation thresholds in 21 
open chest, anesthetized dogs were studied. Defibrillation 
was accomplished using nontruncated exponential pulses 
delivered through two epicardial patches. Multiple shocks 
of varying energy were administered after 10 s of ventric- 
ular fibrillation in random order. The percent success was 
plotted against the energy delivered for each dog. A sigmoi- 
dal curve was lit to the data and the energy associated with 
50% success (Es,,) calculated. Flecainide (n = 16) or saline 
solution (n = 5) was then infused and Es, again determined. 
Flecainide infusion produced mean (+ standard error of 
the mean) plasma levels of 610 + 111 q/ml. 
Defibrillation thresholds were obtainable in 10 of 16 
dogs that received flecainide infusion. Flecainide infusion 
The effect of antiarrhythmic agents on defibrillation thresh- 
old has become an important issue with the increasing 
utilization of the automatic implantable cardioverter- 
defibrillator (AICD) as a safe and effective therapeutic 
approach in patients with life-threatening ventricular ar- 
rhythmias (1.2). Many patients with an AICD also receive 
antiarrhythmic therapy to prevent nonsustained tachycardia 
or to reduce the frequency of sustained ventricular arrhyth- 
mias. Because the AICD delivers a fixed (and, in some 
patients, a marginal) amount of energy, a drug that increases 
the energy required for defibrillation could result in ineffec- 
tive discharge. 
Many ant&rhythmic drugs can affect the energy required 
for defibrillation (3-11). However, little is known about the 
effect of flecainide, a class Ic antiarrhythmic drug effective in 
the treatment of ventricular ectopic rhythms (12-17), on 
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increased E,, by 75% (from 6.5 f 1.9 to 11.4 + 2.6 J) 
(p < 0.05). Infusion of saline solution did not significantly 
affect defibrillation energy. Of 16 dogs that received 
llecainide infusion, 12 had one or more complications: 6 
had ventricular fibrillation resistant to defibrillation, 6 
developed severe hypotension after successful defibrillation 
and 5 had spontaneous ventricular fibrillation after success- 
ful defibrillation. These effects were not seen in any control 
dogs. 
Fleeainide infusion significantly increases defibrillation 
threshold and has important adverse arrhythmic and he- 
modynamic effects in this experimental preparation. 
(J Am Co11 Cardiol1989;14:777-81) 
defibrillation thresholds. Encainide, a similar class Ic antiar- 
rhythmic agent, has been shown to increase defibrillation 
thresholds markedly (9). The present study examines the 
effect of intravenous flecainide on defibrillation threshold in 
the open chest, anesthetized dog. 
Methods 
Animal preparation. Twenty-one male or female adult 
mongrel dogs, weighing 17 to 28 kg (mean 24.1 t 2.4), were 
anesthetized with intravenous sodium pentobarbital (30 mg/ 
kg). Additional doses of pentobarbital were administered as 
needed to maintain a level of anesthesia characterized by 
absence of pedal reflexes. The dogs were intubated and 
ventilated with room air with use of a Harvard respirator. 
Ventilatory variables were adjusted to maintain an arterial 
partial pressure of oxygen (PO,) >60 mm Hg, a partial 
pressure of carbon dioxide (PcoZ) between 25 and 35 mm Hg 
and a pH between 7.35 and 7.45. A heating blanket was used 
to maintain normothermia. Succinylcholine (20 mg, intrave- 
nously) was administered just before the chest was opened. 
The chest was opened through a median stemotomy, and 
the heart was suspended in a pericardial cradle. Two 14 cm* 
rectangular defibrillator patches (CPI model A67) were po- 
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sitioned over the left and right ventricles. For all experi- 
ments, the left ventricular patch was used as the cathode. 
Patches were stabilized with two pericardial sutures. Two 
unipolar epicardial leads (Medtronic model 495 l-35) were 
sutured to the myocardium for epicardial recording and 
pacing. A bipolar electrode was also sutured to the ventric- 
ular epicardium for induction of ventricular fibrillation. The 
chest retractor was then withdrawn. 
per min for 50 min, 0.028 mg/kg per min for 30 min and finally 
0.021 mg/kg per min until completion of the protocol. Forty 
minutes after either flecainide or saline solution infusion was 
started, defibrillation thresholds were again determined, as 
described previously. 
Measurements. Electrocardiographic intervals (RR, PR, 
QRS and QT) were measured every 30 min at a paper speed 
of 100 mm/s (Beckman model R612 recorder). 
In all experiments, a surface electrocardiogram (ECG) 
(bandpass filter 0.15 to 30 cycles/s) and epicardial ECG 
(bandpass filter 30 to 500 cycles/s) were amplified (Gould 
Universal amplifier model 13-4615-58), continuously dis- 
played (Gould oscilloscope model VlOOO) and recorded 
(Gould digital recorder model ESlOOO). The right femoral 
vein was cannulated, and a saline solution infusion (50 to 100 
ml/h) was started to prevent volume depletion. The right 
femoral artery was cannulated for continuous blood pressure 
monitoring (Statham P23Db transducer) and recording 
(Beckman model R612). Arterial blood gases were analyzed 
every 30 min. 
Pacing thresholds were determined with a programmable 
stimulator (Bloom Associates model DTU-201) with use of 
rectangular 0.5 ms pulses at a cycle length of 300 ms before 
and after baseline defibrillation threshold determination and 
before and after flecainide or saline defibrillation threshold 
determination. All pacing thresholds were determined at 
least 3 min after the last defibrillation shock. 
Defibrillation threshold determination. Fibrillation was 
induced with I to 2 s of 60 Hz rectified current (I5 to 30 V). 
After 10 s of ventricular fibrillation, defibrillation was ac- 
complished with a custom-made defibrillator utilizing non- 
truncated exponential pulses of 1.5 ms duration capable of 
delivering 3.3 to 39 J in steps of 1 to 3 J. The initial 
defibrillation shock was 12.5 .I. In subsequent trials, progres- 
sively lower (or higher if 12.5 J was unsuccessful) energy 
levels were tested until first failure (or success) was 
achieved. Two shocks at energy levels 1 to 3 J above and two 
at levels 1 to 3 J below this energy level were then selected 
and delivered four times each in random order, for a total of 
16 defibrillation trials. The percent defibrillation success was 
plotted versus energy level, and the raw data were fit by 
logistic regression (SAS Version 5, SAS Institute, Inc., 
Cary, North Carolina) to a sigmoidal curve (18). The energy 
levels associated with 50 and 80% defibrillation success (E,, 
and E,,, respectively) were obtained from the sigmoidal 
curve. 
Plasma jecainide levels were determined by high per- 
formance liquid chromatography (20), and were obtained 
just before flecainide defibrillation threshold determination 
and every 30 min thereafter. Determination of arterial pH, 
PO, and Pco, was accomplished with a commercial analyzer 
(Corning pHiblood gas analyzer model 16512). 
Statistical analysis. Data are presented as mean values t 
SEM unless otherwise indicated. Energy levels associated 
with 50% and 80% defibrillation success (E,, and Es,, 
respectively) before and after flecainide or saline solution 
infusion were compared by paired t test within the same 
group and by unpaired t test within dtierent groups. Dither- 
ences in ECG intervals and flecainide levels were assessed 
utilizing a t test. A probability (p) value CO.05 was consid- 
ered statistically significant. 
Results 
After any unsuccessful defibrillation, a 39 J rescue shock 
was delivered through the defibrillation patches as rapidly as 
possible (typically 6 to 8 s after the first shock). If required, 
another high energy internal or transthoracic defibrillation 
was performed. Only the first shock was analyzed, and all 
rescue shocks were ignored. At least 3 min was allowed after 
arterial blood pressure had returned to a stable level for 
recovery between fibrillation/defibrillation sequences. 
Electrocardiographic intervals. Flecainide levels ranged 
from 165 to 1,060 drnl (mean 610 t 111 &ml). Flecainide 
infusion did not significantly modify RR, QT or corrected QT 
intervals, but was associated with a 17% increase in QRS 
duration (from 58 * 3 to 68 + 4 ms; p < 0.05) and a 13% 
increase in PR interval (from 102 + 5 to 116 2 5 ms; 
p < 0.05). 
Pacing thresholds. Baseline pacing thresholds were not 
significantly different for dogs receiving saline solution or 
flecainide infusion (0.50 ? 0.07 and 0.68 2 0.10 V, respec- 
tively). For all dogs, pacing threshold increased after base- 
line defibrillation threshold determination. Flecainide infu- 
sion significantly increased pacing threshold (3.10 ? 0.99 V) 
compared with saline infUsion (1.18 f 0.71 V; p < 0.05). 
After defibrillation energy was determined in the control Defibrillation thresholds. Defibrillation threshold could 
state, the dogs received an infusion of eitherjecainide (16 be determined at baseline and after saline infusion in all five 
dogs) or saline solution (5 dogs). The flecainide infusion was control dogs. Defibrillation threshold was determined at 
calculated, based on the method of separate exponentials baseline in all 16 dogs that received flecainide, but in only 10 
(19), to maintain a concentration in the range of 400 to 600 of the 16 after flecainide infusion for reasons discussed later. 
&ml. Flecainide was administered as a 1 mg/kg bolus over Percent defibrillation success versus defibrillation energy 
10 min, followed by a rapid loading infusion of 0.032 mg/kg level for a typical dog receiving flecainide is shown in Figure 
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Figure 1. Defibrillation curves before and during flecainide infusion 
in a single dog. Lines representing the sigmoidal relation, fit by 
logistic regression analysis, of percent defibrillation success and 
energy level and raw data are shown. The predicted energy levels 
associated with 50% defibrillation success (E,,) before and after 
Aecainide infusion are illustrated; E,, increased from 5.7 to 9.6 J. 
1. The energy level associated with a 50% defibrillation 
success (E,,,) before (baseline) and after saline or flecainide 
infusion for all dogs is shown in Figure 2. There was no 
difference in baseline E,, for control and flecainide-treated 
Fllure 2. Baseline and infusion energy associated with 50% de- 
fibrillation success for dogs receiving saline solution (n = 5) or 
flecainide (n = IO). 
rpNS1 ~p=.ooo~ 
. 
‘3i 30 
b) 
3 
1 
l-----PNS----l 
0 
2 / 
2 
8 
2 
/ 
; 20 
5: . 
Flecainide 
Control Infusion 
) p : .002 -l 
Ip NSl 
Saline 
Control Infusion 
. . 
Flecainide 
Control Infusion 
Figure 3. Baseline and infusion energy associated with 80% de- 
fibrillation success for animals receiving saline solution (n = 5) or 
flecainide (n = 10). 
animals (9.2 + 2.7 and 6.5 * 1.9 J, respectively; p = NS). 
Infusion of saline solution did not significantly affect E,, or 
Es,. Flecainide infusion increased E,, in 8 of 10 dogs, and in 
2 dogs, E,, was unchanged. The mean E,, was increased 
75% (from 6.5 -C 1.9 to 11.4 5 2.6 J; p < 0.05) by flecainide 
infusion; the mean change in ES,, during flecainide infusion 
(an increase of 4.7 f 1.2 J) was significantly different from 
the change during infusion of saline solution (a decrease of 
0.3 + 0.4 J; p < 0.05). Flecainide infusion increased the 
energy level associated with 80% defibrillation success from 
8.1 2 1.8 to 12.9 * 2.8 J; p < 0.05) (Fig. 3). 
Complications. In six dogs, defibrillation thresholds 
could not be determined after flecainide infusion (in four 
because ventricular fibrillation during the infusion was re- 
fractory to defibrillation, and in two because severe and 
prolonged hypotension developed during the infusion after 
an unsuccessful defibrillation trial, when a rescue shock 
restored sinus rhythm). Ventricular fibrillation refractory to 
defibrillation was observed in two additional dogs during 
flecainide infusion, although defibrillation threshold could be 
determined in these dogs. Ventricular fibrillation refractory 
to defibrillation was never observed after infusion of saline 
solution or in dogs before infusion. Severe and prolonged 
hypotension was observed in a total of six dogs during 
flecainide infusion after rescue defibrillation. In all six dogs, 
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cardiac massage was performed for several minutes. In four 
of the six, hemodynamic stability returned and the protocol 
could be completed. Again, severe hypotension was never 
seen before Recainide infusion or in control dogs. Spontane- 
ous ventricular tachycardia or flutter was observed in five 
dogs after they had undergone successful defibrillation dur- 
ing flecainide infusion. Flecainide level, QRS duration and 
PR interval did not distinguish between dogs that experi- 
enced these complications and those that did not. 
Discussion 
these dogs and did not include them in the calculation of 
Effect of fkcainide on defibrillation threshold. 
defibrillation energy. In the 10 dogs that received flecainide 
For the first 
time, this study demonstrates that flecainide administered 
infusion and completed the protocol, the increase in E,, 
intravenously increases the energy required for successful 
defibrillation in the open chest, anesthetized dog. The energy 
level associated with a 50% success rate (E,,) was increased 
by a mean of 75%. This increase is probably an underesti- 
mation because four dogs with ventricular fibrillation refrac- 
tory to defibrillation were excluded from the calculation. 
Because of the statistical nature of the relation between 
defibrillation success and energy level, we did not assign an 
energy level higher than that of the last unsuccessful trial for 
Other effects of flecainide. During flecainide infusion, 8 of 
Class Ic antiarrhythmic agents may, by some unknown 
16 dogs died (6 because of refractory ventricular fibrillation 
and 2 because of severe hypotension) before the completion 
mechanism, exacerbate this phenomenon. 
of the protocol (in 2, defibrillation thresholds could still be 
determined). Similar problems have been observed with 
encainide, an electrophysiogically related agent. Fain et al. 
Study limitations. For pragmatic reasons, we examined 
(9) reported that 5 of 13 dogs receiving encainide or its 
metabolite 0-demethyl-encainide could not be defibrillated 
even at high energy, although all but I could eventually be 
resuscitated after several minutes of cardiac massage. Re- 
fractory ventricular fibrillation in which resuscitation is more 
difficult than previously studied or impossible to accomplish 
has been reported in patients treated with oral flecainide 
(25,26), but no systematic studies in animal models have 
been reported. In our study, refractory fibrillation and 
severe hypotension were seen in 12 of 16 dogs that received 
flecainide and usually in the first unsuccessful trial. These 
complications were never observed in the five control dogs. 
It may be the combination of flecainide and prolonged 
fibrillation (and perhaps a preceding ineffective discharge) 
that is responsible for these deleterious outcomes. Longer 
fibrillation time has been reported (27) to increase the energy 
requirements for fibrillation and to cause more postshock 
hemodynamic depression than shorter fibrillation periods. 
ranged from 0% (in two dogs) to 260%. Energy levels that 
were 90% effective in each animal before flecainide infusion 
achieved only 40 2 10% success during flecainide infusion. 
This increase in defibrillation threshold occurred with 
flecainide levels considered to be reasonable and therapeutic 
in animals and humans (l&21). Neither ECG interval, 
flecainide level nor baseline defibrillation energy predicted 
the magnitude of the increase in individual dogs. 
Comparison with other antiarrhythmic drugs. Many other 
antiarrhythmic drugs, including quinidine (3), lidocaine (3,6- 
8), diphenylhydantoin (3) and amiodarone (IO), have been 
shown to increase the defibrillation threshold. However, at 
therapeutic levels of these antiarrhythmic drugs. the in- 
crease in defibrillation thresholds has been moderate (gener- 
ally <50%). In contrast, encainide, another class Ic antiar- 
rhythmic agent, increased the energy level associated with 
50% defibrillation success (E,,) by 129% in an experimental 
preparation similar to ours (9). It appears that class Ic agents 
may increase defibrillation thresholds to a greater degree 
than do other antiarrhythmic agents. Class Ic agents are 
unique in their ability to increase pacing threshold (22,23); 
this may be related to the increase in defibrillation threshold 
because myocardial capture and depolarization of a critical 
ventricular mass are required for defibrillation (24). For 
individual dogs in our study, however, the increase in 
defibrillation energy did not correlate with observed increase 
in pacing threshold. 
the effects of intravenous flecainide in an anesthetized ani- 
mal model. We cannot directly apply our observations to the 
effects of oral flecainide in humans. Nevertheless, we be- 
lieve our results may have clinical implications for the 
following reasons: 1) the plasma flecainide levels observed in 
our study are comparable with those observed clinically; 2) 
flecainide does not appear to undergo biotransformation 
after oral administration, and the metabolites are not be- 
lieved to have any important effects (21); 3) no significant 
pharmacodynamic differences between oral or intravenous 
flecainide have been reported; and 4) pentobarbital anesthe- 
sia has negligible effects on defibrillation threshold (28). 
Another potential experimental problem was the require- 
ment for multiple fibrillatiunldeJihri/lation trials. Several 
methods have been used to define defibrillation energy 
requirements; the data suggest that there is not a clear 
distinction between effective and ineffective energies (18). 
Defibrillation energy requirements are probably best de- 
scribed by a curve expressing the relation between energy 
and the probability of successful defibrillation. Definition of 
this relation requires multiple fibrillation/defibrillation trials 
but, as has been demonstrated, these curves are reproduc- 
ible, stable over time (18) and probably not influenced by the 
number of delivered shocks or by the time interval between 
shocks (29,30). In our study, the stability of the defibrillation 
success versus energy curve in saline-treated control dogs 
argues that the repeated trials did not influence the results. 
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Conclusions. We observed that intravenous flecainide in 
doses that are commonly used increases the energy required 
for successful defibrillation and that this effect cannot be 
predicted by plasma drug concentration or ECG intervals. 
Flecainide may also have important adverse arrhythmic and 
hemodynamic effects in this setting. The implications of 
these findings for patients with an implanted automatic 
cardioconverter-defibrillator who are receiving oral flecain- 
ide are unclear, but suggest the potential for dangerous 
interactions. 
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